Status:
COMPLETED
Evaluation of PD 0348292 for Preventing Blood Clots in the Lungs or Deep Leg Veins of Patients After Knee Surgery
Lead Sponsor:
Pfizer
Conditions:
Venous Thrombosis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
To study the safety and effectiveness of several doses of PD 0348292 compared to enoxaparin in preventing blood clots in the lungs or deep leg veins of patients after knee surgery
Eligibility Criteria
Inclusion
- Adult men or women scheduled for an elective, unilateral total knee replacement who are otherwise healthy.
Exclusion
- History of deep vein thrombosis or pulmonary embolism, suspected postthrombotic state, bleeding or clotting disorders, or cardiovascular, renal or liver disease within the past year
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
End Date :
July 1 2007
Estimated Enrollment :
1225 Patients enrolled
Trial Details
Trial ID
NCT00306254
Start Date
March 1 2006
End Date
July 1 2007
Last Update
October 10 2007
Active Locations (134)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Birmingham, Alabama, United States, 35205
2
Pfizer Investigational Site
Birmingham, Alabama, United States, 35209
3
Pfizer Investigational Site
Little Rock, Arkansas, United States, 72205
4
Pfizer Investigational Site
North Little Rock, Arkansas, United States, 72118